BioSpring GmbH
Dr. Christina Lehmann is a seasoned professional in the field of quality assurance and life sciences, currently serving as Quality Assurance Manager at Biospring GmbH since September 2019. Prior experience includes roles as Specialist for Deviations and CAPA, Consultant, Change Control Specialist, and Training Compliance Support at agap2 Deutschland - Life Sciences from October 2017 to August 2019. Dr. Lehmann's academic background includes a PhD research focus at Goethe-Universität Frankfurt a. Main, analyzing biomechanics in C. elegans embryos, complemented by internships at the Max-Planck-Institute for Heart and Lung Research and the Max Planck Institute for Brain Research, focusing on embryonic development. Dr. Lehmann holds a Master of Science and Bachelor of Science in Cell Biology and Physiology and Biowissenschaften from Goethe University Frankfurt.
This person is not in any offices
BioSpring GmbH
BioSpring is a leading industry expert in oligonucleotide science and technology, specializing in high-quality cGMP manufacturing and analytics for commercial programs and clinical phases I-III, in addition to preclinical material supply and diagnostic manufacturing. We are a privately owned company of ~600 employees committed to providing expert support through all phases and regulatory filings, including highly flexible and customizable solutions to accelerate therapeutic programs through the entire drug development lifecycle. Headquartered in the center of Europe, in Frankfurt, Germany, we are an international company with a subsidiary in the United States and a local presence in Japan. Our global clients can rely on our quality and expertise, guided by our passion for innovation and more than 27 years of experience. Our aim is a highly collaborative partnership to unleash the full potential of our clients’ technology – making great strides and breakthroughs possible. We are driven by our desire for a healthier world. Restoring hope in patients living with debilitating diseases is our daily motivation to progress novel nucleic acid-based therapies to their commercial promise. Privacy notice: https://www.biospring.de/datenschutz-socialmedia/